COVID-19: DCGI Nod To SII For Phase 2 & 3 Human Clinical Trials Of Oxford Vaccine Candidate

by M. Nuruddin Aug 03, 2020 • 05:14 PM Views 790

Pune-based Serum Institute of India (SII) has been given a green light by the Drugs Controller General of India (DCGI) for conducting the Phase 2 and 3 human clinical trials of the Covid-19 vaccine candidate developed by Oxford University, news agency PTI has reported. SII, the world's largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by University of Oxford’s Jenner Institute in collaboration with British-Swedish company AstraZeneca.